
The listed Danish medtech company, ChemoMetec, is launching the latest edition to its portfolio, the cell count device NC-250. The product was scheduled for launch this spring.
According to the company, the NC-250 is a virtually maintenance-free device with very low associated costs. With the launch ChemoMetec expects to increase market shares within the markets for life science research and pharmaceutical quality control and production.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app